疾病
发病机制
医学
淀粉样蛋白(真菌学)
临床试验
靶向治疗
阿尔茨海默病
阿尔茨海默病的生物化学
淀粉样β
τ蛋白
β淀粉样蛋白
生物信息学
神经科学
淀粉样前体蛋白
免疫学
病理
心理学
内科学
生物
癌症
作者
Jiyi Xu,Zhi Zhou,Qin Bin
出处
期刊:Chinese Journal of Geriatrics
日期:2019-12-14
卷期号:38 (12): 1441-1444
标识
DOI:10.3760/cma.j.issn.0254-9026.2019.12.030
摘要
The theory of amyloid-induced Alzheimer's disease(AD)has been challenged by the scientific community.However, with the deep study of amyloid beta(Aβ)cascade metabolic reaction process and the characteristics and functions of various Aβ polypeptides, people have a profound understanding of the pathogenesis of AD caused by Aβ.Currently, several Aβ antibodies, including the protofibril selective antibody BAN2401, are in clinical trials for treating Alzheimer's disease.After the good results of targeted therapy for Aβ(Ban2401), this theory has attracted our attention again.In this paper, the pathogenesis of Aβ and the progress of targeted therapy were reviewed systematically.
Key words:
Alzheimer disease; Amyloid; Targeted therapy
科研通智能强力驱动
Strongly Powered by AbleSci AI